UNSPSC 51362307: Zolpidem tartrate

This classification denotes a sedative and hypnotic with the molecular formula 2C19H21N3O.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WY6W63843K, chemically known as n,n,6-trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide but more generally known as zolpidem tartrate, which bears US NIH Compound Identifier 5732. European Medicines Agency schedules Zolpidem tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05192MIG.

UNSPSC 51362307 Zolpidem tartrate is a Commodity code that captures individual pharmaceutical products—in this case, a sedative-hypnotic medication—procured by state and local health agencies, departments of human services, and cooperative purchasing alliances for distribution through state pharmacy networks, community health programs, and employee benefit plans. State and local buyers solicit zolpidem tartrate and similar generic pharmaceuticals through both direct product procurement (where the drug itself is the line item) and broader multi-source pharmaceutical agreements that bundle dozens or hundreds of drugs under a single contract framework. Issuing bodies include state health departments, county health systems, state human services commissions, and multistate cooperative purchasing organizations. The work involves vendors supplying FDA-compliant products with full manufacturing documentation, maintaining specific wholesaler relationships, managing pricing transparency, and meeting strict supply-chain security and Good Manufacturing Practice certifications.

Recent activity shows three distinct procurement approaches. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 (response deadline March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, requiring vendors to work through three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards. The Texas Health and Human Services Commission posted a Request for Information in April 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, signaling early-stage state interest in alternative pharmacy distribution models. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure naloxone and drug deactivation systems, representing a narrower, condition-specific pharmaceutical procurement for county community health. Geographic activity spans the upper Midwest (Minnesota), the Southwest (Texas), and the Southeast (Florida), with multistate cooperative purchasing agreements extending procurement reach beyond individual state lines. The recent solicitation mix reflects a market moving from traditional three-wholesaler distribution models toward direct manufacturer relationships and specialized pharmaceutical products for public health emergencies or harm-reduction initiatives.